clinical trial · NCT06875973
Pelacarsen Roll-over Extension Program
Atherosclerotic Cardiovascular DiseasePelacarsen (TQJ230)
brief summary
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
started
May 19, 2025
primary completion
Dec 8, 2030
completion
Dec 8, 2030
last updated
Jun 11, 2026
detailed description
This study will evaluate long-term safety and tolerability of pelacarsen (TQJ230) 80 mg Once a month (QM) in patients with elevated Lp(a) and established ASCVD. All consenting participants from the parent study who meet the eligibility criteria will be participating in this open label extension study.
official title
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol